focus -WSS

focus

author：comprehensive 2025-10-02 19:39:29 - browse：5

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Group behind ProMed defends move to subscription

WSS

Victims of gun violence feel impacts long after bullet wound

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

A controversial new treatment promises to make little people taller

FDA approves Sage Therapeutics’ rapid

Biotech incubator Curie.Bio graduates its first startup

FDA approves potent Eli Lilly obesity drug, Zepbound

Wikipedia

focus

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Pharma showers House GOP doctor with campaign cash

Bright Health sells Medicare Advantage business to Molina

FDA scientists endorse Pfizer/BioNTech Covid

Medical records are filled with copy

The a glaring gap in research on serious mental illness and primary care

Malaria cases in Florida and Texas: Here’s what you need to know

FDA approves Recor Medical high blood pressure device

Dobbs anniversary: the lost opportunity of abortion as health care

Victims of gun violence feel impacts long after bullet wound

entertainment

The cancer stories no one wants to hear

Alnylam reports growth in sales of rare disease treatments

How to ethically and practically extend health care to all

FDA approves potent Eli Lilly obesity drug, Zepbound

Ambulance rides for just $100? Advisers want major billing fixes

Florida officials tell state schools to teach AP Psychology 'in its entirety'

knowledge

explore

leisure time

entertainment